These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 24890535)

  • 21. Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure.
    Gopal DM; Kommineni M; Ayalon N; Koelbl C; Ayalon R; Biolo A; Dember LM; Downing J; Siwik DA; Liang CS; Colucci WS
    J Am Heart Assoc; 2012 Oct; 1(5):e000760. PubMed ID: 23316284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.
    Rørth R; Jhund PS; Yilmaz MB; Kristensen SL; Welsh P; Desai AS; Køber L; Prescott MF; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
    Circ Heart Fail; 2020 Feb; 13(2):e006541. PubMed ID: 32065760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure (from the EVEREST Trial).
    Vaduganathan M; Greene SJ; Ambrosy AP; Mentz RJ; Fonarow GC; Zannad F; Maggioni AP; Konstam MA; Subacius HP; Nodari S; Butler J; Gheorghiade M;
    Am J Cardiol; 2013 Dec; 112(11):1763-9. PubMed ID: 24095030
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of Biomarkers to Predict Readmission for Congestive Heart Failure.
    Sudharshan S; Novak E; Hock K; Scott MG; Geltman EM
    Am J Cardiol; 2017 Feb; 119(3):445-451. PubMed ID: 27939586
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of galectin-3 and plasma B type-natriuretic peptide in predicting prognosis in discharged chronic heart failure patients.
    Feola M; Testa M; Leto L; Cardone M; Sola M; Rosso GL
    Medicine (Baltimore); 2016 Jun; 95(26):e4014. PubMed ID: 27368017
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of high-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide predicts future hospital admission for heart failure in high-risk hypertensive patients with preserved left ventricular ejection fraction.
    Okuyama R; Ishii J; Takahashi H; Kawai H; Muramatsu T; Harada M; Yamada A; Motoyama S; Matsui S; Naruse H; Sarai M; Hasegawa M; Watanabe E; Suzuki A; Hayashi M; Izawa H; Yuzawa Y; Ozaki Y
    Heart Vessels; 2017 Jul; 32(7):880-892. PubMed ID: 28154958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial.
    Gheorghiade M; Böhm M; Greene SJ; Fonarow GC; Lewis EF; Zannad F; Solomon SD; Baschiera F; Botha J; Hua TA; Gimpelewicz CR; Jaumont X; Lesogor A; Maggioni AP;
    JAMA; 2013 Mar; 309(11):1125-35. PubMed ID: 23478743
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The utility of galectin-3 for predicting cause-specific death in hospitalized patients with heart failure.
    Zhang Y; Zhang R; An T; Huang Y; Guo X; Yin S; Wang Y; Ji S; Lv R; Zhang J; Maisel A
    J Card Fail; 2015 Jan; 21(1):51-9. PubMed ID: 25463412
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study.
    Motiwala SR; Szymonifka J; Belcher A; Weiner RB; Baggish AL; Sluss P; Gaggin HK; Bhardwaj A; Januzzi JL
    Eur J Heart Fail; 2013 Oct; 15(10):1157-63. PubMed ID: 23666680
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Utility of galectin-3 as a prognostic biomarker in heart failure: where do we stand?
    Srivatsan V; George M; Shanmugam E
    Eur J Prev Cardiol; 2015 Sep; 22(9):1096-110. PubMed ID: 25268020
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolic profile provides prognostic value better than galectin-3 in patients with heart failure.
    Wang CH; Cheng ML; Liu MH; Kuo LT; Shiao MS
    J Cardiol; 2017 Jul; 70(1):92-98. PubMed ID: 28318874
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel discharge risk model for patients hospitalised for acute decompensated heart failure incorporating N-terminal pro-B-type natriuretic peptide levels: a European coLlaboration on Acute decompeNsated Heart Failure: ELAN-HF Score.
    Salah K; Kok WE; Eurlings LW; Bettencourt P; Pimenta JM; Metra M; Bayes-Genis A; Verdiani V; Bettari L; Lazzarini V; Damman P; Tijssen JG; Pinto YM
    Heart; 2014 Jan; 100(2):115-25. PubMed ID: 24179162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT.
    Anand IS; Rector TS; Kuskowski M; Adourian A; Muntendam P; Cohn JN
    Eur J Heart Fail; 2013 May; 15(5):511-8. PubMed ID: 23291728
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Admission, discharge, or change in B-type natriuretic peptide and long-term outcomes: data from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) linked to Medicare claims.
    Kociol RD; Horton JR; Fonarow GC; Reyes EM; Shaw LK; O'Connor CM; Felker GM; Hernandez AF
    Circ Heart Fail; 2011 Sep; 4(5):628-36. PubMed ID: 21743005
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A pooled analysis of multicenter cohort studies of (123)I-mIBG imaging of sympathetic innervation for assessment of long-term prognosis in heart failure.
    Nakata T; Nakajima K; Yamashina S; Yamada T; Momose M; Kasama S; Matsui T; Matsuo S; Travin MI; Jacobson AF
    JACC Cardiovasc Imaging; 2013 Jul; 6(7):772-84. PubMed ID: 23845574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serial galectin-3 and future cardiovascular disease in the general population.
    van der Velde AR; Meijers WC; Ho JE; Brouwers FP; Rienstra M; Bakker SJ; Muller Kobold AC; van Veldhuisen DJ; van Gilst WH; van der Harst P; de Boer RA
    Heart; 2016 Jul; 102(14):1134-41. PubMed ID: 27084804
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk prediction for 30-day heart failure-specific readmission or death after discharge: Data from the Korean Acute Heart Failure (KorAHF) registry.
    Lim NK; Lee SE; Lee HY; Cho HJ; Choe WS; Kim H; Choi JO; Jeon ES; Kim MS; Kim JJ; Hwang KK; Chae SC; Baek SH; Kang SM; Choi DJ; Yoo BS; Kim KH; Cho MC; Oh BH; Park HY
    J Cardiol; 2019 Feb; 73(2):108-113. PubMed ID: 30360893
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Catheter ablation of atrial fibrillation reduces heart failure rehospitalization in patients with heart failure with preserved ejection fraction.
    Fukui A; Tanino T; Yamaguchi T; Hirota K; Saito S; Okada N; Akioka H; Shinohara T; Yufu K; Takahashi N
    J Cardiovasc Electrophysiol; 2020 Mar; 31(3):682-688. PubMed ID: 31985099
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Validated, electronic health record deployable prediction models for assessing patient risk of 30-day rehospitalization and mortality in older heart failure patients.
    Eapen ZJ; Liang L; Fonarow GC; Heidenreich PA; Curtis LH; Peterson ED; Hernandez AF
    JACC Heart Fail; 2013 Jun; 1(3):245-51. PubMed ID: 24621877
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [BNP-guided therapy optimizes the timing of discharge and the medium term risk stratification in patients admitted for congestive heart failure].
    Valle R; Aspromonte N; Carbonieri E; De Michele G; Di Tano G; Giovinazzo P; Cioè R; Di Giacomo T; Milani L; Noventa F; Chiatto M
    Monaldi Arch Chest Dis; 2007 Sep; 68(3):154-64. PubMed ID: 18361212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.